Press Releases

Algeta ASA (OSL:ALGETA) Oslo, Norway, 19 September 2008 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, announced today that the third quarter results will be presented on 5 November, not on November 12 as previously announced.

For further information, please contact

Thomas Ramdahl, CEO +47 23 00 79 90 / +47 913 91 458 (mob) Øystein Soug, CFO +47 23 00 79 84 / +47 906 56 525 (mob) post@algeta.com



About Algeta Algeta ASA is a Norwegian cancer therapeutics company built on world-leading, proprietary technology. Algeta is developing new, targeted cancer therapeutics that harness the unique characteristics of alpha particle emitters and are potent, well-tolerated and convenient to use.

Algeta's lead product candidate, Alpharadin, has commenced an international phase III clinical trial in hormone-refractory prostate cancer (ALSYMPCA) based on positive phase II results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from multiple cancer types, as well as primary bone cancers. Algeta is also developing other technologies for delivering alpha emitters. These include microparticles, liposomes, and methods to enhance the potency of therapeutic antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227. The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).

Alpharadin and Algeta are trademarks of Algeta ASA.

###



LINK: http://hugin.info/134655/R/1252804/272609.pdf

Algeta ASA

http://www.algeta.com

ISIN: NO0010239437

Stock Identifier: XOSL.ALGETA